Legend Biotech Names Veteran Finance Executive Gareth Kung to Board and Audit Chair Role
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Legend Biotech ( (LEGN) ) has issued an update.
On February 2, 2026, Legend Biotech Corporation appointed veteran finance executive Gareth Kung to its board of directors as a Class II director, with a term running through the company’s 2028 annual general meeting, and named him chair of the audit committee, replacing Tomas Heyman. Kung, currently a senior advisor at Wuhan Xinxin Semiconductor Manufacturing in China and formerly CFO or senior finance leader at multiple global semiconductor, solar and IT services companies, brings extensive cross-border capital markets and governance experience; his compensation package includes a three-year vesting restricted share unit award valued at $270,000 on grant, plus annual cash retainers for board and audit chair service, signaling Legend Biotech’s continued emphasis on strengthening its financial oversight and board expertise as it advances its growth strategy.
The most recent analyst rating on (LEGN) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.
Spark’s Take on LEGN Stock
According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.
The score is most constrained by weak financial performance (ongoing losses and negative operating/free cash flow) and bearish technicals (price below major moving averages with negative MACD). These are partially offset by a positive earnings-call outlook driven by strong CARVYKTI growth, expanding international demand, and improved labeling that could support the path to profitability.
To see Spark’s full report on LEGN stock, click here.
More about Legend Biotech
Legend Biotech Corporation is a foreign private issuer in the biopharmaceutical sector, listed in the United States and headquartered in Somerset, New Jersey. The company focuses on developing and commercializing advanced therapies, with its governance and disclosure practices aligned to U.S. securities regulations through Form 20-F reporting and related SEC registrations.
Average Trading Volume: 2,544,788
Technical Sentiment Signal: Sell
Current Market Cap: $3.08B
For an in-depth examination of LEGN stock, go to TipRanks’ Overview page.
